REG - RTW Biotech Opp. - GSK to acquire RAPT Therapeutics

RTW Biotech OpportunitiesAnnouncement

21/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260121:nRSU6698Pa&default-theme=true

RNS Number : 6698P  RTW Biotech Opportunities Ltd  21 January 2026

LEI: 549300Q7EXQQH6KF7Z84

21 January 2026

RTW Biotech Opportunities Ltd

GSK to acquire RAPT Therapeutics

·      Transaction values RAPT at approximately $2.2 billion

·      Acquisition price of $58 per share represents a 65% premium to
closing share price on 19 January

·      As at 31 December 2025, RAPT represented 0.15% of the Company's
NAV

 

RTW Biotech Opportunities Ltd ("the Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to the note the announcement by GSK, plc. ("GSK" LSE/NYSE: GSK) that it has
entered into a definitive agreement to acquire public portfolio company RAPT
Therapeutics, Inc. ("RAPT" Nasdaq: RAPT).

RAPT is a California-based clinical-stage biopharmaceutical company developing
therapies for patients living with inflammatory and immunologic diseases. The
acquisition includes ozureprubart, a monoclonal antibody treatment that RAPT
had advanced to Phase 2b for prophylactic protection against food allergens,
which affect more than 17 million patients in the US alone.

 

RAPT shareholders will receive $58 per share in an all-cash transaction that
values RAPT at $2.2 billion and is expected to be completed in the first
quarter of 2026. The acquisition price represents a 65% premium to RAPT's
closing share price on 19 January, prior to the announcement. As at 31
December 2025, RAPT represented 0.15% of the Company's NAV.

 

Rod Wong, CIO of RTW Investments, said, "We are pleased to see GSK recognize
the innovative work being done at RAPT, the potential of ozureprubart, and the
promise it holds for patients living with severe food allergies. This is the
second acquisition from the Company's portfolio so far in 2026, following
Boston Scientific's acquisition of Penumbra last week. We think that 2026 will
be a stand-out year for biotech M&A as policy risks recede and large
pharmas seek to replenish their pipelines in the face of a cumulative $170
billion patent cliff looming by 2032."

 

RAPT's announcement can be found here
(https://investors.rapt.com/news-releases/news-release-details/gsk-enters-agreement-acquire-rapt-therapeutics)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager  +44 (0)20 7959 6362

 Oliver Kenyon                             biotechopportunities@rtwfunds.com

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                           +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)               +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker   +44 (0)20 7260 1000

 Nathan Brown

 Duncan Monteith

 BofA Securities - Joint Corporate Broker  +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                  +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/) for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUPPUCPGUPQGMU



            Copyright 2019 Regulatory News Service, all rights reserved